Unravelling the binding and activation mechanism of a complex G protein-coupled receptor [ 2016 - 2019 ]

Research Grant

Researchers: Prof Ross Bathgate (Principal investigator) ,  A/Pr Paul Gooley ,  Dr Daniel Scott ,  Dr Michael Griffin

Brief description The peptide hormone relaxin is currently in a Phase III trial for the treatment of heart failure. However the peptide is not a good drug as it can't be taken orally and is very expensive to produce. We will study the interaction of relaxin with its cell surface receptor and the mechanisms by which the receptor functions. The knowledge gained will aid in the design of smaller, more potent and orally active forms of relaxin for the treatment of heart failure

Funding Amount $AUD 1,072,921.44

Funding Scheme Project Grants

Notes Standard Project Grant